• 5040 Corporate Plaza Drive, Suite 7R, Colorado Springs, CO 80919
  • 719-347-5400
  • info@realmofcaring.org
  • 719-347-5400
  • info@realmofcaring.org
  • Home
  • Research
    • Research Library
    • Participate in Research
    • Observational Research Registry (ORR)
  • Resources
    • Aspen Green Giveaway
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
      • Client Additional Questions
    • Healthcare Portal
      • Practitioner Introduction
      • Cannabinoid Info
      • Practitioner Education Series
    • Blog
    • Find a Provider
    • Printable Resources
    • F.A.Q.
    • Best Practices
    • Glossary
  • About
    • What We Do
    • Who We Serve
    • Financials
    • Our Team
    • Supported Brands
    • Our Sponsors
  • Contact Us
Menu
  • Home
  • Research
    • Research Library
    • Participate in Research
    • Observational Research Registry (ORR)
  • Resources
    • Aspen Green Giveaway
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
      • Client Additional Questions
    • Healthcare Portal
      • Practitioner Introduction
      • Cannabinoid Info
      • Practitioner Education Series
    • Blog
    • Find a Provider
    • Printable Resources
    • F.A.Q.
    • Best Practices
    • Glossary
  • About
    • What We Do
    • Who We Serve
    • Financials
    • Our Team
    • Supported Brands
    • Our Sponsors
  • Contact Us
  • Donate
  • Register
  • Login
  • Home
  • Research
    • Research Library
    • Participate in Research
    • Observational Research Registry (ORR)
  • Resources
    • Aspen Green Giveaway
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
      • Client Additional Questions
    • Healthcare Portal
      • Practitioner Introduction
      • Cannabinoid Info
      • Practitioner Education Series
    • Blog
    • Find a Provider
    • Printable Resources
    • F.A.Q.
    • Best Practices
    • Glossary
  • About
    • What We Do
    • Who We Serve
    • Financials
    • Our Team
    • Supported Brands
    • Our Sponsors
  • Contact Us
Menu
  • Home
  • Research
    • Research Library
    • Participate in Research
    • Observational Research Registry (ORR)
  • Resources
    • Aspen Green Giveaway
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
      • Client Additional Questions
    • Healthcare Portal
      • Practitioner Introduction
      • Cannabinoid Info
      • Practitioner Education Series
    • Blog
    • Find a Provider
    • Printable Resources
    • F.A.Q.
    • Best Practices
    • Glossary
  • About
    • What We Do
    • Who We Serve
    • Financials
    • Our Team
    • Supported Brands
    • Our Sponsors
  • Contact Us
  • Register
  • Login

Research Library

A-Z Conditions  Participate in ORR

Therapeutic Use of Cannabis in Inflammatory Bowel Disease

  • Journal : Gastroenterology & Hepatology
  • Publication Year : 2016
  • Authors : Waseem Ahmed, MD and Seymour Katz, MD

The marijuana plant Cannabis sativa and its derivatives,cannabinoids, have grown increasingly popular as a potential therapy for inflammatory bowel disease (IBD). Studies have shown that modulation of the endocannabinoid system, which regulates various functions in the body and has been shown to play a key role in the pathogenesis of IBD, has a therapeutic effect in mouse colitis. Epidemiologic data and human therapy studies reveal a possible role for cannabinoids in the symptomatic treatment of IBD, although it has yet to be determined in human populations whether cannabinoids have therapeutic anti-inflammatory effects in IBD or are simply masking its many debilitating symptoms. Large, doubleblind, randomized, placebo-controlled trials using serial inflammatory markers, biopsy findings, and endoscopic disease severity to demonstrate objective improvement in IBD are necessary before cannabis can be empirically accepted and recommended as an IBD treatment option. Questions concerning its safety profile and adverse effects prompt the need for further research, particularly in regard to dosing and route of administration to maximize benefits and limit potential harms. Cannabis use should be reserved for symptomatic control in patients with severe IBD refractory to the currently available standard-of-care and complementary and alternative medicines.

Read the Full Article

Share This:

Twitter Facebook LinkedIn Email
PrevPreviousCannabinoid Delivery Systems for Pain and Inflammation Treatment
NextBronchodilator Effect of Delta-TetrahydrocannabinolNext

Conditions:

  • Gastrointestinal Disease, Irritable Bowel Syndrome

Research Information:

Research Keywords:

Search the Research Library >

Follow Us:

Facebook
Twitter
Youtube

REGISTER WITH THE RoC TODAY!

Realm of Caring focuses on research, education, building community, and improving quality of life. We are an educational resource for consumers, physicians, scientists, governments and the media.
Register now
  • 5040 Corporate Plaza Drive, Suite 7R, Colorado Springs, CO 80919
  • 719-347-5400
  • info@realmofcaring.org

RESEARCH

  • Observational Research Registry
  • Research Library
  • Participate in Research

EDUCATION

  • Client Portal
  • For Pets
  • Client Education Series
  • Glossary

COMMUNITY

  • Share Your Story
  • Volunteer
  • Internships

SUPPORTED BRANDS

  • Aspen Green
  • Charlotte’s Web
  • Elixinol
  • Stanley Brothers™
  • Stratos

Copyright © 2021 / Realm of Caring Foundation, Inc

  • Privacy
  • Disclaimer